A team of researchers from Collegium Medicum at Nicolaus Copernicus University, Department of Cardiology and Internal Diseases, led by Professors Jacek Kubica and Eliano Navarese, are starting a unique research project assessing the impact of two widely available cardiovascular drugs on the course of SARS-CoV-2 infection.
As CLINSCIENCE, we proudly support the research team in the regulatory processes, being in line with our mission to help our partners develop and conduct clinical trials, supporting the launch of new products that improve patients’ expectancy and quality of life.
We believe that the development of clinical trials requires continuous improvement.
To support the R&D activities more effectively, we’ve joined forces and knowledge of the two CRO companies – BIOSCIENCE and CLINMED creating Clinscience.
We are developing a CRO company, which thanks to the use of combined knowledge, unique technology and global access to patients, will allow us effectively implement your research and development processes.
We are excited that Bioscience will be a part of the most comprehensive Outsourcing event which takes place in Boston next month.
To meet with Beata Maciejewska, Bioscience’s Chief Operations Officer and Barbara Mazur – Head of Outsourcing Department please contact us at:
Let’s talk about opportunities to grow your business together.
Please visit the event’s website to know more: https://www.arena-international.com/octnewengland/
Bioscience provides comprehensive services and the most effective technological solutions on the market.
*Offer valid while supplies last.
Biotechnological Company Moleculin Biotech, Inc. Begins Clinical Testing Site Development Efforts in Poland; Selects Bioscience SA as Polish CRO.
Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at the MD Anderson Cancer Center.
“Engaging Bioscience gives us experienced boots on the ground in Poland,” commented Walter Klemp, CEO of Moleculin, “which we believe is critical, not only for ensuring tight coordination between the US and Polish sites in our upcoming Annamycin clinical trial (which would commence only if our IND for Annamycin is permitted), but also to ensure we have the full benefit of local knowledge regarding site performance and regulatory compliance.”
Mr. Klemp continued: “one of the biggest challenges for most clinical trials is recruiting the right patients on a timely basis. We believe adding Polish sites to our planned trial introduces a significant population of qualified patients, and selecting Bioscience helps ensure we reach those patients effectively and efficiently.”
More about Moleculin: http://ir.moleculin.com/
Our Bioscience SA team is proud to announce that we are conducting a clinical trial of influenza biosensor developed by SensDx, which aims to prove the efficacy of test. Other SensDx’s biosensors, made specially for hospital-acquired infections and urology indications are planned to enter clinical trials this year.
Contact Bioscience’s team members to get more info on our solutions!
On December 4th, Beata Maciejewska our Clinical Research Director attended the “Biological drugs – legal aspects” conference (PL: Leki biologiczne – aspekty prawne), which took place at the Cardinal Wyszyński University in Warsaw. For more info (in Polish), please visit: https://lnkd.in/e9x6F7g
On November 14th our Operational Director Przemysław Magielski was a speaker at the „Od pomysłu do Startupu” (EN: “From idea to Startup”) conference, organized by The Cardinal Wyszynski Institute of Cardiology in Warsaw. More info (Polish) at: https://lnkd.in/eMJSvkt